ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like <b>Lexington Biosciences</b> Introduces President And Board Chair May 25, 2017 Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer April 6, 2017 Spark Therapeutics Jumps as FDA Panel Backs Breakthrough Gene Therapy October 12, 2017
Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer April 6, 2017
